The Affimer platform has proven to be outstanding inside the laboratory. Avacta could be a titan in the making. That’s for sure.
Avacta – the next Roche?

Notes on a small investment portfolio
The Affimer platform has proven to be outstanding inside the laboratory. Avacta could be a titan in the making. That’s for sure.
I’m currently looking for additional investment opportunities as soon as possible. Ideally it would be good to diversify into a new sector – although I am equally tempted to find a new green-tech company to invest in.
I bought this at 69.5p, after asking for advice on a fast growing stock which might benefit from the COVID-19 crisis.